Actively Recruiting
Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis
Led by Innodem Neurosciences · Updated on 2026-04-01
168
Participants Needed
2
Research Sites
313 weeks
Total Duration
On this page
Sponsors
I
Innodem Neurosciences
Lead Sponsor
N
Novartis Pharmaceuticals
Collaborating Sponsor
AI-Summary
What this Trial Is About
This study aims to develop and validate a sensitive and non-invasive eye-tracking software application. This study will obtain participant responses to brief cognitive tests designed to evaluate several key functions known to be affected by MS and non-invasive eye movement measurements in response to visually presented stimuli during specifically designed eye-tracking tests. The study data will be used to develop machine learning algorithms and validate a software application intended to track the progressive component of multiple sclerosis and associated cognitive changes.
CONDITIONS
Official Title
Development of a Novel Functional Eye-Tracking Software Application for Multiple Sclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able to provide informed consent.
- Aged 18 years or older at the time of enrollment.
- Able to read in either French or English.
- Visual acuity of 20/100 or better in at least one eye (corrective lenses or surgery allowed).
- Confirmed diagnosis of MS with no progressive increase in physical disability in the past six months.
- Neurologically stable condition during study visit.
- Expanded Disability Status Scale (EDSS) score between 0 and 8.0 at initial visit.
You will not qualify if you...
- History of psychiatric issues affecting movement and eye control.
- Other neurological conditions affecting eye movements (e.g., strabismus, cranial nerve palsy, stroke-related hemianopsia).
- Macular edema or other eye conditions preventing eye movement tests.
- Recent start, dose change, or irregular use of drugs affecting eye movement (e.g., benzodiazepines, antipsychotics, anticonvulsants) within three months.
- For healthy controls: history of neurodegenerative diseases such as MS, Parkinson's, ALS, or dementia.
- For MS patients: diagnosis of Clinically Isolated Syndrome, Radiologically Isolated Syndrome, or Primary Progressive MS.
- MS patients currently experiencing or having experienced a relapse within the past three months.
- MS patients on disease-modifying therapy for less than three months.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
The Neuro
Montreal, Quebec, Canada, H3A 2B4
Actively Recruiting
2
Genge Partners, Inc.
Montreal, Quebec, Canada, H4A 3T4
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
5
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here